DiaSorin S.p.A.

Milan Stock Exchange:DIA.MI

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

🩺 Medical Instruments

💻 Telehealth

Location

Italy

Market Cap

USD 5.89 B

Share Price

USD 108.71

Avg Daily Volume

152,641

Change (1 day)

1.66%

Change (1 year)

4.38%

Change (YTD)

4.93%

DiaSorin S.p.A. Share Price Year-To-Date (YTD) return on June 20, 2025: 4.93%

DiaSorin S.p.A. Share Price Year-To-Date (YTD) return is 4.93% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

DiaSorin S.p.A. 52-week low Share Price is USD 118.68 on June 20, 2025, which is 9.17% above the current Share Price.
DiaSorin S.p.A. 52-week low Share Price is USD 98.95 on June 20, 2025, which is -8.98% below the current Share Price.
DiaSorin S.p.A. average Share Price for the last 52 weeks is USD 108.57.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

Milan Stock Exchange: DIA.MI

DiaSorin S.p.A.

CEO	Mr. Carlo Rosa
IPO Date	July 19, 2007
Location	Italy
Headquarters	Via Crescentino snc
Employees	3,249
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 🩺 Medical Instruments 💻 Telehealth

Description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.